Search 

REM Analytics is a research and development service organisation, helping our customers develop and commercialise new products fast.
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. Our lead asset is ready for clinical development in 2021 and expect to reach PoC in myocardial infarction within 3 years.

Respinova has developed a novel non-invasive technology that aims to treat the core of the COPD pathophysiology – small airway collapse.

Respinova's solution uses unique pulses of air pressure generated by a proprietary device called PulseHaler™. ​The small airways have no cartilage structural support and are totally dependent on the tethering forces of the surrounding lung. When these forces are diminished, the small airways collapse and do not permit airflow to the gas-exchanging alveolar zone of the lung. When COPD starts, airways initially reopen on inspiration. Once the disease progresses, the airways open only on deep inspiration, and finally not at all. When the small airways collapse, not only is gas exchange is impaired, but also the cilia clearing mechanism fails, and secretions accumulate to further worsen the situation.

The small airways have little or no smooth muscle in their walls so that neither beta-adrenergic nor muscarinic drugs can open them up, even if the particles manage to be delivered to the small airways.

The PulseHaler™ generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, thereby creating multiple momentary dilating forces that help gently pry open the collapsed airways. PulseHaler™ also generates positive pressure on exhalation, which helps with airway opening. The pulses also help in smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Satya is a discovery stage oncology biotech, focused on first-in-class and best-in-class programs targeting oncogenes and the DDR pathway. The company's multiple programs are at Hit and Hit-Lead stages, and Satya aims to have unique compound profiles that address specific patient populations with potential for bio-marker based patient selection strategies. Satya is seeking licensing and collaboration opportunities for its programs on a geography-specific or global basis.

Selfit is a digital therapy startup focusing on the aging population and brain and heart conditions.
The company has developed a therapist robot based on AI and neuroscience with focus on physical and cognitive health.

Founded in 1990, Zhejiang Jingxin Pharmaceutical Co., Ltd. is a listed pharmaceutical company integrating R&D, production and sales.
The company is a national key high-tech enterprise, with a national enterprise technology center, post-doctoral research station, provincial key enterprise research institute, provincial academician expert workstation, provincial high-tech enterprise R & D center, and Shanghai Research Institute in Shanghai Zhangjiang Hi-Tech Park.
Jingxin Pharmaceutical adheres to the mission of meticulously guarding health and is committed to becoming a front runner in neurological and cardiovascular therapy areas in China.
No. 70 pharmaceutical companies in China.

The Telocyte Mission:
The use of innovative advanced regenerative cell and gene therapies to reset the cell senescence that underlies and defines the "aging process". Cell senescence instigates a cascade of pathology that causes age- related disease, as our telomeres shorten and modulate the changing pattern of gene expression – the epigenetic signalling information – in aging cells. This is the fundamental problem of aging and age-related disease. To be effective, national healthcare systems need to support the ability to maintain normal cell function as we age, both preventing age-related disease and lowering healthcare costs
Our first clinical target is Alzheimer’s disease.

TRACTIVUS is a company derived from the research group GEMAT (IQS-Ramón Llull University) and IDIBELL (Bellvitge Biomedical Research Institute), located in Barcelona. We are an innovative company with expertise in antibacterial coatings, easy to be implemented on a wide range of medical devices.

PHOBOSTech™ technology have been developed over the years in Tractivus SL as a solution to the current problems of medical devices. Our cost-effective patented technology allows to create nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization. As a result our devices show higher lifetime, lower associated costs, and no post-implantation problems without adverse effect on the patients.

Tractivus SL combines the experience of the research groups and a unique solution designed to root out the colonization of the devices through a micro- and nano-structured coating that protects the device from adhesion and bacterial colonization. The team has worked on all aspects of the development: material selection, regulatory strategy, risk reduction, clinical trials, partners, stakeholders... aiming to maximize the success of both the project and the investors.

Trove is a semi-virtual biotech start-up located in Rockville, Maryland, USA, developing an advanced biologic asset and seeking funding and partners to conduct clinical trials in respiratory disease. We have data and drug supply on our lead, clinical-stage biologic asset to support up to 3 clinical trials in different respiratory conditions (2 x Phase 1b/2a in COVID and lung transplant; and 1 x Phase 2 in chronic sinusitis). Our biologic, called Therabron, is a replacement for a normally abundant native protein that is deficient in our targeted indications. Replacement therapies have a high approval rate with FDA (>70%) and patients with genetic deficiencies can be selected in some trials to increase our chances of demonstrating efficacy. Therabron was safe in 3 early studies. At present, the quickest path to an approval is likely an Emergency Use Authorization in severe COVID-19 patients, so we're looking for an initial $2M seed/Series A round to fund a Phase 1b/2a clinical trial then need another $16M to produce more drug and perform a convincing Phase 2 trial. We are already talking to several potential corporate partners, have signed one CDA with a top 5 pharma, and a relatively small amount of investment in clinical proof of concept demonstrations will attract at least one partner. Once clinical POC is established in targeted indications, we plan to exit via sale/acquisition or out-license. Our markets are large (3 products x >$1B each US) and deal comps in the respiratory space are $250M each and up. We can maximize our ROI by out-licensing the first indication and re-investing upfront license payment proceeds to advance the drug in further indications, depending on what happens in each field/indication and what we (management team and investors) decide to do.